Abstract
Engrailed-2 (EN2) has been identified as a candidate oncogene in breast cancer and prostate cancer. It is usually recognized as a mainly nuclear staining in the cells. However, recent studies showed a cytoplasmic staining occurred in prostate cancer, bladder cancer and clear cell renal cell carcinoma. The inconsistency makes us confused. To clarify the localization and expression of EN2 in renal cell carcinoma, anti-EN2 antibody (ab28731) and anti-EN2 antibody (MAB2600) were used for immunohistochemistry (IHC) respectively. Interestingly, we found that EN2 detected by ab28731 was mainly presented in cytoplasm while EN2 detected by MAB2600 was mainly presented in nucleus. To further investigate the different patterns observed above, lysates from full-length EN2 over expression in HEK293T cells were used to identify which antibody the EN2 molecule bound by western blot. Results showed ab28731 did not react with the lysates. For this reason, the novel specific protein detected by ab28731 was not the EN2 molecule and was named nonEN2. Then using the renal carcinoma tissue microarray and renal tissues, we found that the protein expression levels of nonEN2 in kidney tumor tissues was significantly lower than that in kidney normal tissues (p < 0.05), so was in renal cell lines. Taken together, nonEN2 is lower expressed and may play an important role in renal cell carcinoma.
Highlights
Renal cell carcinoma (RCC) is one of most common lethal malignancies and its incidence is increasing year by year with developed improved diagnosis [1]
71 cases of kidney clear cell carcinoma (CCRCC), 13 kidney transitional cell carcinoma (TCC), 2 each of kidney carcinoma sarcomatodes (CS), papillary renal cell carcinoma (PRCC) and chromophobe carcinoma (CC), plus 10 normal kidney tissue (N), duplicate cores per case was performed for IHC by a polyclonal rabbit anti-EN2 antibody ab28731
Renal clear cell carcinoma tissue microarray BC07114 including 71 cases of kidney clear cell carcinoma (CCRCC), 13 kidney transitional cell carcinoma (TCC), 2 each of kidney carcinoma sarcomatodes (CS), papillary renal cell carcinoma (PRCC) and chromophobe carcinoma (CC), plus 10 normal kidney tissue (N), duplicate cores per case was performed for IHC by ab28731
Summary
Ruili Guan 1,2,3, Yongde Xu 1, Hongen Lei 1, Zhezhu Gao 1, Zhongcheng Xin 1,* and Yinglu Guo 2,3,*. Received: 10 March 2014; in revised form: 2 April 2014 / Accepted: 14 April 2014 /
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.